Loading
Linnaeus Therapeutics is a New Jersey biotech whose oral drug LNS8801 activates the oestrogen receptor GPER, a pathway that pushes melanoma cells to stop dividing and become visible to the immune system.
Linnaeus Therapeutics develops LNS8801, an orally available agonist of the G protein-coupled oestrogen receptor (GPER), based on University of Pennsylvania research showing that GPER activation drives melanoma differentiation and lowers c-Myc. LNS8801 has been tested alone and with pembrolizumab in phase 1/2 trials in cutaneous melanoma and uveal melanoma, including patients who had progressed on checkpoint inhibitors.
LNS8801 is an experimental investigational agent whose form is not stated in the registry from Linnaeus Therapeutics in phase 3 trials for melanoma, aimed at Estrogen receptor (ERα).